Details of the Drug

General Information of Drug (ID: DMA6D5V)

• Drug Name: SMT-19969
• Synonyms: Small-molecule antibacterial agents (Clostridium difficile infection), Summit

Indication

Disease Entry	ICD 11	Status	REF
C. difficile infection	1A04	Phase 3	[1]

• Chemical Identifiers:
  Formula: C24H16N6
  Canonical SMILES: C1=CC2=C(C=C1C3=CC4=C(C=C3)N=C(N4)C5=CC=NC=C5)NC(=N2)C6=CC=NC=C6
  InChI: InChI=1S/C24H16N6/c1-3-19-21(29-23(27-19)15-5-9-25-10-6-15)13-17(1)18-2-4-20-22(14-18)30-24(28-20)16-7-11-26-12-8-16/h1-14H,(H,27,29)(H,28,30)
  InChIKey: UHQFBTAJFNVZIV-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 16659285
  ChEBI ID: CHEMBL3753858
  CAS Number: 308362-25-6
  UNII: 06DX01190R
  DrugBank ID: DB15308
  TTD ID: D04FXY

References

• [1] ClinicalTrials.gov (NCT03595566) To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (Ri-CoDIFy 2). U.S. National Institutes of Health.